Cardiovascular and Metabolism
Novartis is focused on improving the lives of the hundreds of millions of people with cardiovascular and metabolic diseases and provides therapies and support programs to treat high blood pressure and diabetes - both major public health issues.
The portfolio includes the following treatments for high blood pressure:*
- Diovan (valsartan), an angiotensin receptor blocker (ARB)
- Co-Diovan/Diovan HCT (valsartan and hydrochlorothiazide)
- Exforge (amlodipine and valsartan), a single pill combining two high blood pressure medicines
- Tekturna/Rasilez (aliskiren), a direct renin inhibitor
- Tekturna HCT/Rasilez HCT (aliskiren with hydrochlorothiazide)
- Valturna (aliskiren with valsartan), available in the US
The following oral treatments are for the management of type 2 diabetes:*
- Galvus (vildagliptin), a DPP-4 inhibitor
- Eucreas (vildagliptin and metformin)
Learn more about our products for cardiovascular and metabolic conditions
*Not all indications are available in all countries.
Innovative medicines
Research
Novartis is one of the industry’s biggest investors in research.
Patient groups
Our commitment to high-quality healthcare has led to an enduring and trusted partnership between Novartis and various patient groups.
